Claims for Patent: 8,080,518

Summary for Patent: 8,080,518

Title:	Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
Abstract:	The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
Inventor(s):	Tymianski; Michael (Toronto, CA), Garman; Jonathan David (San Jose, CA)
Assignee:	Arbor Vita Corporation (Fremont, CA) Nono Inc. (Toronto, Ontario, CA)
Application Number:	12/323,915
Patent Claims:	1. A method of delivering a pharmacologic agent to a subject, the method comprising: administering the pharmacologic agent linked to an internalization peptide to the subject; and administering an anti-inflammatory agent to the subject, whereby the anti-inflammatory agent inhibits an inflammatory response from mast cell degranulation induced by the internalization peptide; wherein the pharmacological agent is a peptide having an amino acid sequence comprising ESDV (SEQ ID NO:12) or ETDV (SEQ ID NO:40) and the internalization peptide has an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51). 2. The method of claim 1, wherein the anti-inflammatory agent is an anti-histamine. 3. The method of claim 1, wherein the anti-inflammatory agent is a corticosteroid. 4. The method of claim 1, wherein the internalization peptide is a tat peptide having an amino acid sequence comprising GRKKRRQRRR (SEQ ID NO:1). 5. The method of claim 1 wherein the internalization peptide is a tat peptide having an amino acid sequence comprising YGRKKRRQRRR (SEQ ID NO:2). 6. The method of claim 1, wherein the internalization peptide is a tat peptide having an amino acid sequence comprising GRKKRRQRRRP (SEQ ID NO: 69). 7. The method of claim 1, wherein the pharmacologic agent is KLSSIESDV (SEQ ID NO:5). 8. A method of treating or effecting prophylaxis of a disease characterized by excitotoxicity comprising administering to a subject having or at risk of the disease a pharmacologic agent that inhibits binding of PSD95 to NDMAR 2B linked to an internalization peptide in a regime effective to treat or effect prophylaxis of the disease; and administering to the subject an anti-inflammatory agent, whereby the anti-inflammatory agent inhibits an inflammatory response from mast cell degranulation induced by the internalization peptide wherein the pharmacological agent is a peptide having an amino acid sequence comprising ESDV (SEQ ID NO:12) or ETDV (SEQ ID NO:40) and the internalization peptide has an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51). 9. The method of claim 8, wherein the internalization peptide is a tat peptide having an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51), GRKKRRQRRR (SEQ ID NO:1), YGRKKRRQRRR (SEQ ID NO:2), FGRKKRRQRRR (SEQ ID NO:3) or GRKKRRQRRRPQ (SEQ ID NO:4). 10. The method of claim 8, wherein the subject is female. 11. The method of claim 8, wherein the disease is stroke or traumatic injury to the CNS not involving stroke. 12. The method of claim 8, wherein the subject is at risk of transient cerebral ischemic attack or stroke as a result of undergoing heart surgery. 13. In a method of delivering a pharmacologic agent linked to an internalization peptide to a subject, the improvement wherein the internalization peptide is administered with a mast cell degranulation inhibitor to inhibit mast cell degranulation inducible by the internalization peptide, wherein the pharmacological agent is a peptide having an amino acid sequence comprising ESDV (SEQ ID NO:12) or ETDV (SEQ ID NO:40) and the internalization peptide has an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51). 14. A method of delivering a pharmacologic agent to a subject the method comprising: administering the pharmacologic agent linked to an internalization peptide to a subject, wherein the subject has been or will be administered a mast cell degranulation inhibitor within a time window starting six hours before and ending one hour after the pharmacologic agent is administered) to inhibit mast cell degranulation inducible by the internalization peptide, wherein the pharmacological agent is a peptide having an amino acid sequence comprising ESDV (SEQ ID NO:12) or ETDV (SEQ ID NO:40) and the internalization peptide has an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51. 15. The method of claim 1, wherein the anti-inflammatory agent is a mast cell degranulation inhibitor. 16. The method of claim 8, wherein the anti-inflammatory agent is a mast cell degranulation inhibitor. 17. The method of claim 13, wherein the mast cell degranulation inhibitor is administered within a time window starting six hours before and ending one hour after the pharmacologic agent is administered. 18. The method of claim 1, wherein the anti-inflammatory agent is administered intravenously. 19. The method of claim 8, wherein the mast cell degranulation inhibitor is administered intravenously. 20. The method of claim 14, wherein the mast cell degranulation inhibitor is administered intravenously.

Details for Patent 8,080,518

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2027-12-05